Literature DB >> 1636239

Bacillus Calmette-Guérin immunotherapy. Techniques and results.

S A Brosman1.   

Abstract

Intravesical instillation of bacillus Calmette-Guérin (BCG) has become an important adjunct in the management of patients with stages Ta and T1 transitional-cell carcinoma of the bladder and carcinoma in situ (CIS). For BCG to be effective, patients should be assigned to the appropriate protocol. With proper treatment, tumor recurrences can be prevented in as many as 80% of patients, residual tumor eradicated in 60%, and CIS eliminated in 70% of appropriately selected patients.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1636239

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  8 in total

1.  Chest wall abscess due to Mycobacterium bovis BCG after intravesical BCG therapy.

Authors:  Hajime Kanamori; Katsuhiko Isogami; Takashi Hatakeyama; Hiroo Saito; Kazuyoshi Shimada; Bine Uchiyama; Noboru Aso; Mitsuo Kaku
Journal:  J Clin Microbiol       Date:  2011-11-23       Impact factor: 5.948

2.  PCR identification of Mycobacterium bovis BCG.

Authors:  E A Talbot; D L Williams; R Frothingham
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas.

Authors:  J Cresswell; H Robertson; D E Neal; T R Griffiths; J A Kirby
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.

Authors:  M D Melekos; I Zarakovitis; K Dandinis; E Fokaefs; H Chionis; H Dauaher; G Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

5.  Specific differentiation between Mycobacterium bovis BCG and virulent strains of the Mycobacterium tuberculosis complex.

Authors:  J Magdalena; P Supply; C Locht
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

Review 6.  BCG in the treatment of superficial cancer of the bladder: a review.

Authors:  S Friberg
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

Review 7.  Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.

Authors:  M M Walther; W D Figg; W M Linehan
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

8.  Chemopreventive effect of Lactobacillus rhamnosus on growth of a subcutaneously implanted bladder cancer cell line in the mouse.

Authors:  Boon-Kian Lim; Ratha Mahendran; Yuan-Kun Lee; Boon-Huat Bay
Journal:  Jpn J Cancer Res       Date:  2002-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.